In this work, the authors observed an increase of survival of AIDS patients after the oral treatment with N-acetylcysteine (NAC) administration, a precursor of GSH [22, 23]
Structural modifications extend its working window in research settings
Serious Gastrointestinal Risks: While it mentions "changes in digestion," it omits potential severe side effects such as pancreatitis, gallbladder disease, and the risk of bowel obstruction/ileus, which are recognized clinical risks
The peptide is expected to stay on the Category 2 list because of a lack of clinical evidence and significant safety concerns
It is a monitoring problem as much as a safety one, and belongs in the conversation with the prescribing provider
Similarly, headaches may arise, often linked to mild dehydration or the initial metabolic shift during the first few weeks of the program